Humanigen Inc (HGENQ)

[cowtown jay]

I wonder if Gilead wishes they had kept a non-exclusive right to use lenzilumab from Humanigen, instead of spending $4.9B on buying Forty Seven, and trying to use magrolimab in 30+ trials.

Maybe management would again license lenz to Gilead, non-exclusively, of course, and maybe for not much more than the $4.9B they spent buying Forty Seven, and maybe not to use for the indications we are pursuing. After all, what are frenemies for?